Please assess the completion status of the following clinical trial:

Trial Title: Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the rectum~* Tumor located within 12cm of anal verge~* Clinical stage of T3-4 or N+ by rectal MRI with or without endorectal ultrasound~* Available tumor samples before study treatment (fresh or paraffin-embedded) for immunohistochemistry (IHC) and methylation-specific PCR (MSP) to investigate MGMT expression and hypermethylation~* Male or female aged over 20 years~* Be ambulatory and have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.~* No prior systemic treatment (chemotherapy, immunotherapy) or radiation therapy~* Adequate major organ functions as following:~* Be willing and able to comply with the protocol for the duration of the study.~* Give written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.~Exclusion Criteria:~* Histology other than adenocarcinoma or tumor arising from inflammatory bowel disease~* Inadequate tumor sample for MGMT IHC or MSP~* Any evidence of systemic metastasis~* Unresected synchronous colon cancer~* Intestinal obstructions or impending intestinal obstruction, but bypass surgery (colostomy or ileostomy) is permitted before study treatment~* Uncontrolled or severe cardiovascular disease~* Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.~* Other malignancy within the past 5 years except cured non-melanomatous skin cancer, carcinoma in situ of the cervix, or thyroid papillary carcinoma.~* Organ allografts requiring immunosuppressive therapy.~* Psychiatric disorder or uncontrolled seizure that would preclude compliance.~* Pregnant, nursing women or patients with reproductive potential without contraception.~* Patients receiving a concomitant treatment with drugs interacting with 5-FU such as flucytosine, phenytoin, or warfarin et al.~* Known dihydropyrimidine dehydrogenase (DPD) deficiency.~* Known hypersensitivity to any of the components of the study medications.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine, Temozolomide, Radiotherapy (Type: EXPERIMENTAL): The total dose of radiotherapy will be 50.4 Gy, with a daily dose of 1.8 Gy administered on 5 days of each week, comprising a total of 45 Gy to the whole pelvis, followed by a 5.4 Gy boost to the primary tumor.~The doses and schedules for capecitabine will be fixed, with only temozolomide being prescribed using a dose-escalation schedule. Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).

Based on this trial design, predict the completion outcome and termination type (if applicable).